Protagen AG and MicroDiscovery GmbH cooperate in biomarker development

(PresseBox) ( Berlin/Dortmund, )
Dortmund based Protagen AG, a specialist in in-vitro diagnostics and GMP-conform protein analytics and MicroDiscovery GmbH, a bioinformatics company based in Berlin, have started a cooperation to identify and validate biomarkers for medically relevant diseases.

„Our proprietary technology platform UNIarray® and MicroDiscovery’s certified software solutions for the analysis of complex marker panels complement each other perfectly,“ states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics of Protagen AG and adds: „The cooperation strengthens our position in biomarker development and supports the efficient development of marketable products.”

Dr. Arif Malik, CEO of MicroDiscovery GmbH, confirms: „Our experience in analyzing clinical studies for multiplex assays and array data perfectly fits with Protagen’s established screening platform. This illustrates the value of MicroDiscovery’s bioinformatics methods and software solutions for the development of new diagnostics.”

About MicroDiscovery GmbH

MicroDiscovery is a leading provider of innovative and certified software solutions for diagnostics, individualized medicine and molecular biological research. The Berlin-based company was founded in the year 2000 and has managed to attract many renowned customers due to its high competence in realizing custom software solutions. This knowhow is combined with complementary services ranging from biostatistical data analysis and algorithm development to bioinformatics assistance for complex research projects.

About Protagen AG

Protagen AG (www.protagen.de), located in Dortmund, Germany, is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.